Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 8/20 | 0.36 |
| ▸ | SLC6A2 known ✓ | P23975 | 7/20 | 0.36 |
| ▸ | SLC6A3 known ✓ | Q01959 | 6/20 | 0.36 |
| ▸ | HTR1A known ✓ | P08908 | 6/20 | 0.36 |
| ▸ | HTR7 known ✓ | P34969 | 1/20 | 0.35 |
| ▸ | MAPK14 known ✓ | Q16539 | 1/20 | 0.34 |
| ▸ | MPO | P05164 | 1/20 | 0.45 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.39 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.39 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.36 |
| ▸ | CCR3 | P51677 | 1/20 | 0.36 |
| ▸ | TDO2 | P48775 | 1/20 | 0.36 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.34 |
| ▸ | CDK9 | P50750 | 2/20 | 0.34 |
| ▸ | CDK1 | P06493 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | CASP3 | P42574 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | CDK7 | P50613 | 1/20 | 0.34 |
| ▸ | CASP7 | P55210 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1843618 | 0.99 | MPO (0.46) | MPOMKNK1MKNK2SLC6A4SLC6A2 | |
| Hydrochloric Acid SCHEMBL8679453 | 0.92 | MPO (0.52) | MPOMKNK1MKNK2TDO2CCNT1 | |
| SCHEMBL14686420 | 0.87 | MPO (0.43) | MPOMKNK1MKNK2SLC6A4SLC6A2 | |
| SCHEMBL1845286 | 0.82 | ACHE (0.35) | MPOSLC6A4 | |
| Hydrochloric Acid SCHEMBL8463063 | 0.79 | HTR2C (0.43) | — | |
| SCHEMBL14685960 | 0.77 | MEN1 (0.43) | — | |
| Hydrochloric Acid SCHEMBL531052 | 0.74 | ACHE (0.60) | SLC6A4HTR7 | |
| SCHEMBL8786866 | 0.74 | ACHE (0.50) | SLC6A4HTR7 | |
| SCHEMBL8788480 | 0.74 | ACHE (0.45) | SLC6A4 | |
| SCHEMBL8506902 | 0.74 | ACHE (0.50) | SLC6A4HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012134445-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF PALIPERIDONE | WATSON LABORATORIES, INC. (US) | 2012-10-04 | — | — | WO | claimed |
| WO-2012123963-A2 | A PROCESS FOR PREPARATION OF ILOPERIDONE AND AMORPHOUS CO- PRECIPITATE OF ILOPERIDONE WITH PHARMACEUTICALLY ACCEPTABLE EXCIPIENT | MEGAFINE PHARMA (P) LTD. (IN) | 2012-09-20 | — | — | WO | claimed |
| EP-2475663-A2 | PALIPERIDONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF SUBSTANTIALLY FREE OF IMPURITIES | Actavis Group Ptc Ehf (IS) | 2012-07-18 | — | — | EP | claimed |
| EP-2300467-A2 | NOVEL AND IMPROVED PROCESSES FOR THE PREPARATION OF PALIPERIDONE | MSN Laboratories Limited (IN) | 2011-03-30 | — | — | EP | claimed |
| WO-2011030224-A2 | PALIPERIDONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF SUBSTANTIALLY FREE OF IMPURITIES | ACTAVIS GROUP PTC EHF (IS) | 2011-03-17 | — | — | WO | claimed |
| EP-2249649-A2 | AN IMPROVED PROCESS FOR PREPARATION OF PALIPERIDONE | Watson Pharma Private Limited (IN) | 2010-11-17 | — | — | EP | claimed |
| WO-2010004578-A2 | NOVEL AND IMPROVED PROCESSES FOR THE PREPARATION OF PALIPERIDONE | MSN LABORATORIES LIMITED (IN) | 2010-01-14 | — | — | WO | claimed |
| WO-2009116071-A2 | AN IMPROVED PROCESS FOR PREPARATION OF PALIPERIDONE | Watson Pharma Private Limited (IN) | 2009-09-24 | — | — | WO | claimed |
| WO-2009016653-A1 | STABLE POLYMORPHIC FORM OF PALIPERIDONE AND PROCESS FOR ITS PREPARATION | NATCO PHARMA LIMITED (IN) | 2009-02-05 | — | — | WO | claimed |
| WO-2007093870-A2 | A PROCESS FOR THE PREPARATION OF RISPERIDONE | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2007-08-23 | — | — | WO | claimed |
| US-6432596-B1 | — | — | None | — | — | US | disclosed |
| US-12429787-B2 | Electronic device and method for producing the same, image forming method, and image forming apparatus | RICOH COMPANY, LTD. (JP) | 2025-09-30 | — | — | US | disclosed |
| US-20230101614-A1 | ELECTRONIC DEVICE AND METHOD FOR PRODUCING THE SAME, IMAGE FORMING METHOD, AND IMAGE FORMING APPARATUS | RICOH COMPANY, LTD. (JP) | 2023-03-30 | — | — | US | disclosed |
| EP-4154329-A1 | METAL OXIDE PARTICLES HAVING P-TYPE SEMICONDUCTIVITY, ELECTRONIC DEVICE USING THE SAME, METHOD FOR MANUFACTURING ELECTRONIC DEVICE, AND IMAGE FORMING APPARATUS | Ricoh Company, Ltd. (JP) | 2023-03-29 | — | — | EP | disclosed |
| WO-2021234469-A1 | METAL OXIDE PARTICLES HAVING P-TYPE SEMICONDUCTIVITY, ELECTRONIC DEVICE USING THE SAME, METHOD FOR MANUFACTURING ELECTRONIC DEVICE, AND IMAGE FORMING APPARATUS | RICOH COMPANY, LTD. (JP) | 2021-11-25 | — | — | WO | disclosed |
| US-5591745-A | ANTIPSYCHOTICS AND ANALGESICS | HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) | 1997-01-07 | — | — | US | disclosed |
| WO-1996032389-A1 | 4-(6-FLUORO-1,2-BENZISOXAZOLYL)-1-PIPERIDINYL-PROPOXY-CHROMEN-4-ONE DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF PSYCHOSIS, SCHIZOPHRENIA AND ANXIETY | FERRER INTERNACIONAL, S.A. (ES) | 1996-10-17 | — | — | WO | disclosed |
| EP-0730452-A1 | HETEROARYLPIPERIDINES, PYRROLIDINES AND PIPERAZINES AND THEIR USE AS ANTIPSYCHOTICS AND ANALGETICS | HOECHST MARION ROUSSEL, Inc. (US) | 1996-09-11 | — | — | EP | disclosed |
| EP-0730594-A1 | NOVEL 9-HYDROXY-PYRIDO [1,2-a]PYRIMIDIN-4-ONE ETHER DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1996-09-11 | — | — | EP | disclosed |
| WO-1995014691-A1 | NOVEL 9-HYDROXY-PYRIDO[1,2-a]PYRIMIDIN-4-ONE ETHER DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1995-06-01 | — | — | WO | disclosed |